PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea

Collaboration combines best-in-class offerings from CHA and PAREXEL
to enhance early phase clinical trials in growing hub for drug
development

BOSTON–(BUSINESS WIRE)–PAREXEL International Corporation, the world’s leading innovator of
biopharmaceutical services, today announced an alliance with CHA Medical
Group (CHA) to enhance early phase clinical development in Korea. The
collaboration is designed to provide biopharmaceutical companies with
comprehensive services that leverage PAREXEL’s global clinical research
and regulatory expertise with CHA’s experience conducting early phase
studies in Korea.

A growing hub for drug development, Korea is ranked sixth in the world
for the number of clinical trials conducted in the country,1
and is an attractive location for early phase trials due to government
investment in the industry and access to patients. Additionally, Korea’s
regulatory requirements, modeled after the U.S. Food and Drug
Administration (FDA), enable sponsors to use the data from early
clinical studies conducted in the country for global development.

“Enrollment challenges are a primary cause of delays in Phase I/II
studies which involve target patient populations, and many companies
struggle with gaining access to patients while conducting trials in a
safe and controlled environment,” said Stanford Jhee, PharmD, Corporate
Vice President, Early Phase Scientific Affairs at PAREXEL. “With this
partnership we are aiming to bring our biopharmaceutical clients
interested in conducting trials in Korea not only broad access to
patients, but the expertise necessary to conduct the trials from start
to finish, generate quality Phase I data needed for global development
and gain the market advantage essential to commercial success.”

PAREXEL has 28 offices and 7,150 employees across the Asia Pacific
region, and established operations in Korea in 2000. Through the
partnership, PAREXEL and CHA have recently completed a Phase I
First-in-Human clinical trial at CHA’s flagship facility in Seoul, South
Korea.

About PAREXEL International

PAREXEL International Corporation is the world’s leading innovator of
biopharmaceutical services. We simplify our clients’ journey of
transforming scientific discoveries into new medical treatments for
patients with high-quality Phase I-IV clinical research, regulatory,
consulting and market access services. PAREXEL develops breakthrough
innovations and solutions by leveraging its comprehensive therapeutic,
technical and functional expertise, in more than 100 countries around
the world. For more information, visit www.PAREXEL.com.

1Business Korea, “Due to High-quality Medical
Services Seoul Ranks First in the World in Number of Clinical Trials per
City.”

Contacts

PAREXEL Contacts:
Media:
Dana Robie
Tel.:
+1 781-434-4772
Email: Dana.Robie@PAREXEL.com
or
Kathryn
McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300
Email:
PAREXEL@pancomm.com